MX2012002768A - Anticuerpos humanizados para peptido-6 derivado de hsp65, metodos y usos de los mismos. - Google Patents
Anticuerpos humanizados para peptido-6 derivado de hsp65, metodos y usos de los mismos.Info
- Publication number
- MX2012002768A MX2012002768A MX2012002768A MX2012002768A MX2012002768A MX 2012002768 A MX2012002768 A MX 2012002768A MX 2012002768 A MX2012002768 A MX 2012002768A MX 2012002768 A MX2012002768 A MX 2012002768A MX 2012002768 A MX2012002768 A MX 2012002768A
- Authority
- MX
- Mexico
- Prior art keywords
- ser
- tyr
- seq
- leu
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1289—Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24021809P | 2009-09-06 | 2009-09-06 | |
| PCT/IL2010/000731 WO2011027349A1 (en) | 2009-09-06 | 2010-09-06 | Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002768A true MX2012002768A (es) | 2012-06-28 |
Family
ID=43648941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002768A MX2012002768A (es) | 2009-09-06 | 2010-09-06 | Anticuerpos humanizados para peptido-6 derivado de hsp65, metodos y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8680241B2 (enExample) |
| EP (2) | EP3366308A1 (enExample) |
| JP (1) | JP5781514B2 (enExample) |
| KR (1) | KR101831229B1 (enExample) |
| CN (1) | CN102740877B (enExample) |
| AU (1) | AU2010290844B2 (enExample) |
| BR (1) | BR112012004983A2 (enExample) |
| CA (1) | CA2772567A1 (enExample) |
| IN (1) | IN2012DN02869A (enExample) |
| MX (1) | MX2012002768A (enExample) |
| RU (1) | RU2596925C2 (enExample) |
| WO (1) | WO2011027349A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2068889T (pt) * | 2006-08-10 | 2020-01-30 | Roy C Levitt | Anakinra para uso no tratamento da síndrome da bronquiolite obliterante |
| JP6829194B2 (ja) * | 2014-10-24 | 2021-02-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法 |
| WO2016116948A1 (en) | 2015-01-22 | 2016-07-28 | Ram Isanaka | Peptide for treating inflammatory diseases |
| WO2017005923A1 (en) * | 2015-07-09 | 2017-01-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vector expressing membrane-anchored or secreted antibody |
| MX385370B (es) * | 2016-03-31 | 2025-03-18 | Immutrix Therapeutics Inc | Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados. |
| PL3830119T3 (pl) * | 2018-08-01 | 2026-05-25 | Imcheck Therapeutics | Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych |
| WO2025155809A2 (en) * | 2024-01-18 | 2025-07-24 | Nextcure, Inc. | Compositions and methods for modulating vstm-1 mediated signal transduction |
| WO2025231127A1 (en) * | 2024-05-02 | 2025-11-06 | The Regents Of The University Of California | Compositions and methods for intracellular antigen targeting with antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| US7488476B2 (en) * | 1998-11-05 | 2009-02-10 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases |
| DE69929454T2 (de) * | 1998-11-05 | 2006-09-28 | Hadasit Medical Research Services & Development Co. Ltd. | Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen |
| WO2003057527A2 (en) * | 2001-12-31 | 2003-07-17 | L.A.S. Trust, Ein 02/6105365 | Recreational vehicle |
| EP1619521A1 (en) | 2004-07-22 | 2006-01-25 | IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. | Capacitive transmitter electrode |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| CA2596833C (en) | 2005-02-03 | 2016-04-12 | Antitope Limited | Human antibodies and proteins |
| CA2619654A1 (en) * | 2005-08-24 | 2007-03-01 | Cell Matrix | Combination therapies for inhibiting integrin-extracellular matrix interactions |
| PT1989544E (pt) | 2006-03-02 | 2011-09-26 | Antitope Ltd | Ensaios com células t |
| US20080019979A1 (en) * | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| WO2008114733A1 (ja) * | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
| MX2010005282A (es) | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| RU2011143776A (ru) | 2009-03-30 | 2013-05-10 | Протаб Лтд. | Белок, ассоциированный с аденилатциклазой (сар1) и применение его в качестве мишени для иммуномодуляции |
| US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
-
2010
- 2010-09-06 EP EP18161381.1A patent/EP3366308A1/en not_active Withdrawn
- 2010-09-06 WO PCT/IL2010/000731 patent/WO2011027349A1/en not_active Ceased
- 2010-09-06 RU RU2012106891/10A patent/RU2596925C2/ru not_active IP Right Cessation
- 2010-09-06 CN CN201080050177.2A patent/CN102740877B/zh not_active Expired - Fee Related
- 2010-09-06 EP EP10813428.9A patent/EP2475383A4/en not_active Withdrawn
- 2010-09-06 KR KR1020127008389A patent/KR101831229B1/ko not_active Expired - Fee Related
- 2010-09-06 US US13/392,548 patent/US8680241B2/en not_active Expired - Fee Related
- 2010-09-06 CA CA2772567A patent/CA2772567A1/en not_active Abandoned
- 2010-09-06 AU AU2010290844A patent/AU2010290844B2/en not_active Ceased
- 2010-09-06 MX MX2012002768A patent/MX2012002768A/es not_active Application Discontinuation
- 2010-09-06 JP JP2012527448A patent/JP5781514B2/ja not_active Expired - Fee Related
- 2010-09-06 IN IN2869DEN2012 patent/IN2012DN02869A/en unknown
- 2010-09-06 BR BR112012004983-6A patent/BR112012004983A2/pt not_active Application Discontinuation
-
2014
- 2014-01-31 US US14/169,996 patent/US20140170138A1/en not_active Abandoned
-
2017
- 2017-04-19 US US15/491,377 patent/US20170218056A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120060224A (ko) | 2012-06-11 |
| WO2011027349A1 (en) | 2011-03-10 |
| IN2012DN02869A (enExample) | 2015-07-24 |
| EP2475383A1 (en) | 2012-07-18 |
| JP2013503852A (ja) | 2013-02-04 |
| CA2772567A1 (en) | 2011-03-10 |
| EP2475383A4 (en) | 2013-07-17 |
| US20170218056A1 (en) | 2017-08-03 |
| BR112012004983A2 (pt) | 2021-02-23 |
| RU2012106891A (ru) | 2013-10-27 |
| KR101831229B1 (ko) | 2018-02-22 |
| CN102740877B (zh) | 2015-01-14 |
| EP3366308A1 (en) | 2018-08-29 |
| US8680241B2 (en) | 2014-03-25 |
| US20120156201A1 (en) | 2012-06-21 |
| RU2596925C2 (ru) | 2016-09-10 |
| US20140170138A1 (en) | 2014-06-19 |
| JP5781514B2 (ja) | 2015-09-24 |
| AU2010290844A1 (en) | 2012-03-15 |
| CN102740877A (zh) | 2012-10-17 |
| AU2010290844B2 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230192835A1 (en) | Optimized anti-tl1a antibodies | |
| RU2687209C1 (ru) | Собачьи антитела с модифицированными последовательностями ch2-ch3 | |
| US20170218056A1 (en) | Humanized antibodies specific for hsp65-derived peptide-6, methods and uses thereof | |
| EP3741777A1 (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| US20230138315A1 (en) | Anti-angptl3 antibody and use thereof | |
| WO2020034941A1 (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| JP7858104B2 (ja) | 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 | |
| EP4660205A1 (en) | Multiple antibodies against human il-36r and/or human il-1r3, and uses thereof | |
| CN114269788B (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
| US20240294633A1 (en) | Antibody specific for anti-bcl-6 antibody and methods of use | |
| CN116606373A (zh) | 新型冠状病毒中和抗体及其用途 | |
| JP2022169737A (ja) | 抗ｒａｍｐ２抗体 | |
| JP2024517985A (ja) | 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー | |
| WO2013172379A1 (ja) | 新規抗体及びその用途 | |
| TW202021983A (zh) | 用於嗜伊紅性氣喘之抗il-33療法 | |
| TW202542202A (zh) | 抗體、抗原結合片段及其醫療用途 | |
| WO2026086834A1 (zh) | 抗ox40抗体在治疗皮炎疾病中的用途 | |
| HK40123789A (en) | Optimized anti-tl1a antibodies | |
| AU2023410319A1 (en) | Anti-human cx3cr1 antibody | |
| HK40042163A (en) | Optimized anti-tl1a antibodies | |
| JP2019089840A (ja) | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 | |
| HK40042163B (en) | Optimized anti-tl1a antibodies | |
| EA044647B1 (ru) | Терапия транстиретинового (ттр) амилоидоза антителами, а также антитела, полученные от человека для указанной терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |